Bristol Myers Ownership
| BMY Stock | USD 61.07 0.65 1.08% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 2 B | Current Value 2 B | Avarage Shares Outstanding 1.8 B | Quarterly Volatility 231.3 M |
Bristol |
Bristol Stock Ownership Analysis
About 81.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 1.38. Bristol Myers Squibb recorded a loss per share of 4.41. The entity last dividend was issued on the 4th of April 2025. The firm had 1000000:95 split on the 7th of August 2001. Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company was founded in 1887 and is headquartered in New York, New York. Bristol-Myers Squibb operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 32200 people. For more info on Bristol Myers Squibb please contact Giovanni Caforio at 609 252 4621 or go to https://www.bms.com.Besides selling stocks to institutional investors, Bristol Myers also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bristol Myers' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bristol Myers' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bristol Myers Quarterly Liabilities And Stockholders Equity |
|
Bristol Myers Insider Trades History
Less than 1% of Bristol Myers Squibb are currently held by insiders. Unlike Bristol Myers' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bristol Myers' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bristol Myers' insider trades
Bristol Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bristol Myers is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bristol Myers Squibb backward and forwards among themselves. Bristol Myers' institutional investor refers to the entity that pools money to purchase Bristol Myers' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of New York Mellon Corp | 2024-12-31 | 24.7 M | Northern Trust Corp | 2024-12-31 | 24.7 M | Primecap Management Company | 2024-12-31 | 22.8 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 22.3 M | Bank Of America Corp | 2024-12-31 | 19.9 M | Independent Franchise Partners Llp | 2024-12-31 | 17.1 M | Amvescap Plc. | 2024-12-31 | 16.4 M | Legal & General Group Plc | 2024-12-31 | 16.1 M | Dodge & Cox | 2024-12-31 | 15.4 M | Vanguard Group Inc | 2024-12-31 | 189.9 M | Blackrock Inc | 2024-12-31 | 157.6 M |
Bristol Myers Squibb Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bristol Myers insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bristol Myers' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bristol Myers insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Greg Meyers over a month ago Disposition of 2543 shares by Greg Meyers of Bristol Myers subject to Rule 16b-3 | ||
Peter Arduini over six months ago Acquisition by Peter Arduini of 825 shares of Bristol Myers subject to Rule 16b-3 | ||
Hoch Lynelle over a year ago Disposition of 1050 shares by Hoch Lynelle of Bristol Myers subject to Rule 16b-3 | ||
Phyllis Yale over a year ago Acquisition by Phyllis Yale of 581 shares of Bristol Myers subject to Rule 16b-3 |
Bristol Myers' latest congressional trading
Congressional trading in companies like Bristol Myers Squibb, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bristol Myers by those in governmental positions are based on the same information available to the general public.
| 2025-02-13 | Representative Julie Johnson | Acquired Under $15K | Verify | ||
| 2025-01-07 | Representative Virginia Foxx | Acquired Under $15K | Verify | ||
| 2024-09-02 | Representative John James | Acquired Under $15K | Verify | ||
| 2024-05-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2024-02-13 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-12-14 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-11-15 | Senator Tommy Tuberville | Acquired Under $15K | Verify | ||
| 2023-09-22 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
| 2023-09-17 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
| 2023-06-13 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2023-02-13 | Senator Dan Sullivan | Acquired Under $15K | Verify | ||
| 2022-07-15 | Senator Shelley Moore Capito | Acquired Under $15K | Verify | ||
| 2021-12-03 | Senator Thomas R Carper | Acquired Under $15K | Verify | ||
| 2020-07-29 | Representative John Rutherford | Acquired Under $15K | Verify | ||
| 2019-08-09 | Representative John Rutherford | Acquired Under $15K | Verify | ||
| 2017-03-02 | Senator James Inhofe | Acquired $15K to $50K | Verify |
Bristol Myers Outstanding Bonds
Bristol Myers issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bristol Myers Squibb uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bristol bonds can be classified according to their maturity, which is the date when Bristol Myers Squibb has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BRISTOL MYERS SQUIBB Corp BondUS110122AB49 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122BB30 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122AX68 | View | |
| US110122AP35 Corp BondUS110122AP35 | View | |
| BRISTOL MYERS SQUIBB Corp BondUS110122AU20 | View | |
| BMY 37 15 MAR 52 Corp BondUS110122DW58 | View | |
| BMY 39 15 MAR 62 Corp BondUS110122DX32 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Bristol Myers Corporate Filings
| 13th of March 2025 Other Reports | ViewVerify | |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.